Australia markets close in 1 hour 12 minutes
  • ALL ORDS

    7,437.20
    -50.50 (-0.67%)
     
  • ASX 200

    7,244.90
    -46.40 (-0.64%)
     
  • AUD/USD

    0.6696
    +0.0001 (+0.01%)
     
  • OIL

    74.18
    -0.07 (-0.09%)
     
  • GOLD

    1,784.60
    +2.20 (+0.12%)
     
  • BTC-AUD

    25,448.24
    -134.72 (-0.53%)
     
  • CMC Crypto 200

    401.96
    +0.16 (+0.04%)
     
  • AUD/EUR

    0.6394
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0578
    -0.0004 (-0.04%)
     
  • NZX 50

    11,638.27
    +6.67 (+0.06%)
     
  • NASDAQ

    11,549.69
    -237.11 (-2.01%)
     
  • FTSE

    7,521.39
    -46.15 (-0.61%)
     
  • Dow Jones

    33,596.34
    -350.76 (-1.03%)
     
  • DAX

    14,343.19
    -104.42 (-0.72%)
     
  • Hang Seng

    19,463.19
    +22.01 (+0.11%)
     
  • NIKKEI 225

    27,714.42
    -171.45 (-0.61%)
     

Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago

Catalyst Biosciences, Inc. (NASDAQ:CBIO) shareholders will doubtless be very grateful to see the share price up 45% in the last quarter. But only the myopic could ignore the astounding decline over three years. In that time the share price has melted like a snowball in the desert, down 71%. Arguably, the recent bounce is to be expected after such a bad drop. Of course the real question is whether the business can sustain a turnaround.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

See our latest analysis for Catalyst Biosciences

Given that Catalyst Biosciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over three years, Catalyst Biosciences grew revenue at 7.6% per year. Given it's losing money in pursuit of growth, we are not really impressed with that. Nonetheless, it's fair to say the rapidly declining share price (down 20%, compound, over three years) suggests the market is very disappointed with this level of growth. While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Of course, revenue growth is nice but generally speaking the lower the profits, the riskier the business - and this business isn't making steady profits.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. So it makes a lot of sense to check out what analysts think Catalyst Biosciences will earn in the future (free profit forecasts).

A Different Perspective

While the broader market lost about 12% in the twelve months, Catalyst Biosciences shareholders did even worse, losing 53%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 7% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 2 warning signs for Catalyst Biosciences (1 makes us a bit uncomfortable) that you should be aware of.

Catalyst Biosciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here